The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global immunomodulators market size reached US$ 187.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 263.9 Billion by 2027, exhibiting a growth rate (CAGR) of 5.76% during 2022-2027.
Immunomodulators are a group of drugs used to modify an immune response against infectious diseases, immunodeficiency, and alterations in antibody transfer. These drugs generally include monoclonal antibodies, cytokines, levamisole, and Bacillus Calmette-Guerin (BCG). They are widely used to treat cancer, asthma, tumors, hereditary angioedema, and autoimmune disorders like pemphigus, lupus, allergies, and rheumatoid arthritis. Nowadays, several healthcare providers are recommending immunomodulators with other agents, such as biologics, for managing inflammatory bowel disease (IBD).
The unhealthy lifestyles of individuals on account of rapid urbanization, inflating income levels, and the increasing consumption of processed food products has led to a significant rise in the prevalence of chronic diseases worldwide. This is further escalating the need for organ transplantation, which is positively influencing the demand for topical immunomodulators as a promising therapeutic agent in organ transplant recipients. Moreover, the rising aging population and the growing number of accidents are also increasing the risk of organ failure. Consequently, several governing and non-governing authorities are encouraging organ donation, which, in turn, is boosting the sales of topical immunomodulators worldwide. Apart from this, the increasing prevalence of IBD and autoimmune disorders is bolstering the market growth. Immunomodulators are also utilized in combination therapy to decrease the long-term need for steroids and prevent recurring flares and treat diseases that do not respond to antibiotics. Furthermore, several immunomodulators, including Fluvoxamine, Tocilizumab, and Baricitinib with Remdesivir, are finding application for treating hospitalized patients with coronavirus disease (COVID-19). Besides this, several product candidates are currently in late-stage clinical trials. The development of these products is anticipated to expand the applications of immunomodulators for treating various life-threatening diseases.
IMARC Group provides an analysis of the key trends in each sub-segment of the global immunomodulators market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product and application.
Breakup by Product:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG and Pfizer Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG and Pfizer Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
Epilepsy Drugs Market by Generation Type (First Generation Drugs, Second Generation Drugs, Third Generation Drugs), Anti-Epileptics Drugs Type (Narrow-Spectrum AEDs, Broad-Spectrum AEDs), Distribution Channel (Hospital Pharmacy, Pharmacy Stores, and Others), and Region 2023-2028
Congestive Heart Failure Drugs Market by Drug Class (ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2023-2028
Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at